Mustang Bio, INC

Mustang Bio has been notified by Nasdaq that its common stock failed to maintain the minimum $1.00 bid price requirement.

Mustang Bio, Inc. announced the termination of its CD20 CAR-T license agreement with Fred Hutch, settling payables for $730,000, and approved significant increases to its employee stock plans at its annual meeting.

The U.S. Food and Drug Administration has granted Orphan Drug Designation to a novel CAR T-cell therapy for recurrent diffuse and anaplastic astrocytoma and glioblastoma, providing significant incentives for its development.

Mustang Bio announces it has regained compliance with Nasdaq's minimum stockholders' equity requirement and meets all requirements for continued listing.

Mustang Bio finalizes the sale of fixed assets and exits its Worcester manufacturing facility to AbbVie for $1.0 million, relocating its headquarters and expecting $2.0 million in lease-related savings over the next 24 months.

Mustang Bio, Inc. obtained shareholder approval via written consent for the issuance of up to 5,475,082 common shares related to outstanding warrants, satisfying Nasdaq Listing Rule 5635(d).

Mustang Bio reported a net loss of $955,000 for the first quarter of 2026, with ongoing concerns about Nasdaq listing compliance and future funding needs.

Mustang Bio reported significantly reduced net losses and increased cash reserves for the nine months ended September 30, 2025, driven by cost-cutting measures and financing activities, despite ongoing going concern doubts and program changes.

Mustang Bio, a clinical-stage biopharmaceutical company, reported significantly reduced net losses and increased cash reserves for the first half of 2025, driven by strategic cost-cutting measures and recent capital raises, though substantial doubt about its going concern status persists.

Mustang Bio reports a net loss of $0.2 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Mustang Bio's Q3 2024 report reveals a significant reduction in operating expenses and a net loss of $14.8 million for the nine-month period, while also highlighting substantial doubt about the company's ability to continue as a going concern.

Mustang Bio's Q2 2024 report reveals significant losses, a strategic pivot towards MB-106, and substantial doubt about the company's ability to continue as a going concern.

Mustang Bio's latest 10-K filing highlights a strategic focus on CAR T therapies, ongoing clinical trials, and significant financial hurdles, including substantial doubt about its ability to continue as a going concern.

Mustang Bio's 10-K filing provides a detailed overview of its capital structure, voting rights, and regulatory environment, highlighting its focus on cell and gene therapies.

Mustang Bio's President, CEO, and Interim CFO, Manuel Litchman, reported a transaction involving the relinquishment of 19 common shares to cover tax liabilities.

Fortress Biotech, a 10% owner and director, acquired 278,385 shares of Mustang Bio common stock as a 2025 annual dividend, increasing its total beneficial ownership to 536,577 shares.

Mustang Bio Director Neil Herskowitz reported a private sale of 247 pre-split common shares at $0.962, with his remaining beneficial ownership adjusted for a recent one-for-fifty reverse stock split.

Mustang Bio Director Adam J. Chill reported the sale of 4 common shares at $0.9548 each, holding 375 shares post-transaction, adjusted for a recent reverse stock split.

Mustang Bio Director David Jin plans to acquire 247 shares of common stock in a private transaction on December 30, 2025, at $0.962 per share, adjusted for a prior reverse stock split.

Fortress Biotech, a 10% owner and director of Mustang Bio, acquired 59,334 shares of common stock as an equity fee, increasing its total beneficial ownership to 258,192 shares.

Mustang Bio, Inc. is calling its stockholders to a virtual Annual Meeting on December 22, 2025, to vote on director elections, auditor ratification, and significant increases to its employee stock purchase and incentive plans.

Mustang Bio's majority stockholders approved the issuance of up to 5,475,082 common shares underlying outstanding warrants to comply with Nasdaq Listing Rule 5635(d).

Mustang Bio informs stockholders of the approval of a warrant share issuance by majority holders via written consent, aimed at complying with Nasdaq listing rules.

Mustang Bio will hold its annual stockholders meeting virtually on December 26, 2024, to elect directors and ratify the appointment of its accounting firm.

Mustang Bio stockholders have approved the issuance of shares underlying certain warrants and a reverse stock split to be implemented at the Board's discretion before June 27, 2025.

Mustang Bio files for a potential offering of common stock, warrants, and pre-funded warrants to advance its CAR T therapy programs.

Mustang Bio plans a public offering of common stock and warrants to fund its CAR T therapy development for hematologic malignancies and solid tumors.

Mustang Bio is registering the resale of up to 6,497,800 shares of its common stock issuable upon the exercise of warrants held by selling stockholders.

Mustang Bio is registering the resale of up to 2,743,530 shares of common stock by selling stockholders upon exercise of warrants.

Mustang Bio is offering up to 15,625,000 shares of common stock and accompanying warrants in a public offering to raise capital for working capital, pipeline development, and general corporate purposes.

Mustang Bio is seeking to raise up to $5 million through a public offering of common stock and warrants to fund working capital and pipeline development.

Fortress Biotech, Inc. has increased its beneficial ownership in Mustang Bio, Inc. to 8.0% following an annual equity grant and maintains a voting majority through preferred stock.

Fortress Biotech, Inc. reported a decrease in its beneficial ownership of Mustang Bio, Inc. common stock to 4.0%, falling below the 5% threshold due to recent equity grants.

Fortress Biotech, Inc. has filed an Amendment No. 5 to its Schedule 13D, updating its beneficial ownership in Mustang Bio, Inc. to 7.9% and reaffirming its control through Class A preferred stock.

Fortress Biotech, Inc. has increased its beneficial ownership in Mustang Bio, Inc. to 12.4% of common stock, primarily through equity grants and preferred stock, solidifying its majority voting control.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a passive beneficial ownership of 4.99% in Mustang Bio, Inc.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in Mustang Bio, Inc.'s common stock as of March 31, 2025.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a collective beneficial ownership of 8.8% in Mustang Bio, Inc., primarily through common stock and exercisable warrants.

Armistice Capital, LLC and Steven Boyd have disclosed a passive beneficial ownership of 5,106,287 shares, representing 9.99% of Mustang Bio, Inc.'s common stock as of December 31, 2024.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a 9.99% beneficial ownership stake in Mustang Bio, Inc. following a recent Securities Purchase Agreement.